Dr. Prasant Kunwar-Pulmonologist,AIIMS

03/05/2026

28/04/2026

छाती तथा फोक्सोसम्बन्धी सम्पूर्ण विशेषज्ञ सेवा उपलब्ध छ।

छाती रोग, अस्थमा (Asthma) लगायतका जटिल रोगहरूको आधुनिक जाँच तथा प्रभावकारी उपचार एउटै छानामुनि प्रदान गरिन्छ। अनुभवी र समर्पित चिकित्सकको परामर्शसँगै तपाईंको फोक्सो स्वास्थ्यको सम्पूर्ण हेरचाह यहाँ सुनिश्चित गरिन्छ।

बिहान : ७:०० बजे देखि ९:३० बजे सम्म
बेलुका : ४:०० बजे देखि ७:०० बजे सम्म
स्थान : ज्योति पथ, बुटवल – ६

सम्पर्क नम्बर: ९८११९११३२६० , ९८६७७४९२०६

स्वस्थ सास, स्वस्थ जीवन। तपाईंको स्वास्थ्य हाम्रो प्राथमिकता।

15/04/2026

The Biologic Revolution in COPD

The successful translation of biologic therapies from severe asthma to COPD represents the most transformative pharmacological advance in the field’s history. The key to this success has been the identification and precise targeting of the T2-high endotype.

Dupilumab (Anti-IL-4Rα): The First Approved Biologic

Dupilumab is a fully human monoclonal antibody that blocks the alpha subunit of the interleukin-4 receptor (IL-4Rα), thereby inhibiting signaling of both IL-4 and IL-13—two central cytokines in T2 inflammation. By blocking this shared receptor, dupilumab has a broader mechanism of action than anti-IL-5 agents, addressing not only eosinophil-driven inflammation but also goblet cell hyperplasia, mucus hypersecretion, airway hyperreactivity, and subepithelial fibrosis mediated by IL-13 [14].

The BOREAS Trial (NEJM, 2023): This pivotal Phase 3 trial randomized 939 patients with COPD, blood eosinophils ≥ 300 cells/µL, and an elevated exacerbation risk despite triple therapy to receive dupilumab 300 mg or placebo subcutaneously every two weeks for 52 weeks. The results were landmark: dupilumab reduced the annualized rate of moderate or severe exacerbations by 30% (rate ratio 0.70; 95% CI, 0.58-0.86; P

10/04/2026

💥 Malignant Mimics of ILD: Comprehensive Overview 💥

This consolidated summary outlines the primary malignancies and neoplastic processes that can clinically and radiologically mimic Interstitial Lung Disease (ILD).

​✅️ Malignant Mimics of ILD: ​Neoplastic lesions often present with "pseudo-ILD" patterns such as ground-glass opacities (GGO), reticulation, and septal thickening. Differentiating these from inflammatory or fibrotic ILD is vital to avoid inappropriate immunosuppressive therapy.

🔵 1.Epithelial & Glandular Malignancies

🔹️​Lepidic Predominant Adenocarcinoma: (Formerly BAC). Presents as persistent GGOs or consolidations.

● ​Mimics: Organizing Pneumonia (OP) or NSIP. ● ​Key Sign: Air bronchograms within stable consolidations that do not respond to steroids.

🔹️​Lymphangitic Carcinomatosis: Hematogenous or lymphatic spread (most common in breast, lung, stomach, or pancreatic cancers).

● ​Mimics: Sarcoidosis or Pulmonary Edema. ● ​Key Sign: Nodular or "beaded" thickening of the interlobular septa with preservation of lung architecture (no honeycombing).

🟢 ​2. Lymphoproliferative Disorders:

🔹️​Primary Pulmonary Lymphoma (MALT): Mucosa-associated lymphoid tissue lymphoma.

● ​Mimics: OP or Lymphocytic Interstitial Pneumonia (LIP). ● ​Key Sign: The "CT angiogram sign" (vessels visible through consolidation) and associated thin-walled cysts.

🔹️​Multicentric Castleman Disease:

● ​Mimics: LIP or Sarcoidosis. ● ​Key Sign: Diffuse centrilobular nodules and prominent lymphadenopathy.

🟣 ​3. Rare & Vascular Malignancies:

🔹️​Leukemic Infiltration: Direct blast cell infiltration of the interstitium.

● ​Mimics: Acute Interstitial Pneumonia (AIP) or drug-induced pneumonitis. ● ​Key Sign: Rapid respiratory failure correlating with high peripheral blast counts.

🔹️​Primary Pulmonary Angiosarcoma:

● ​Mimics: Vasculitis or Goodpasture Syndrome. ● ​Key Sign: Recurrent alveolar hemorrhage, progressive anemia, and diffuse GGOs.

🔹️​Pulmonary Tumor Thrombotic Microangiopathy (PTTM):

● ​Mimics: Miliary TB or Hypersensitivity Pneumonitis (HP). ● ​Key Sign: Tree-in-bud pattern and severe pulmonary hypertension out of proportion to the parenchymal lung disease.

🔴 ​4. Other Metastatic Patterns:

🔹️​Malignant Melanoma:

● ​Mimics: Miliary TB or Sarcoidosis. ● ​Key Sign: Can present with a diffuse miliary/infiltrative pattern rather than the typical large nodules.

✅️ ​Differential Comparison between Neoplastic Mimic & Primary ILD:

👉 Neoplastic Mimic:

🔹️GGOs: Adenocarcinoma, Angiosarcoma

🔹️Nodular Septal Thickening: Lymphangitic Carcinomatosis.

🔹️Tree-in-bud / Centrilobular: PTTM, MALT Lymphoma.

🔹️Bilateral Consolidations: Lymphoma, Mucinous Adenocarcinoma.

🔹️Diffuse Nodules/Miliary: Metastatic Melanoma, PTTM.

👉 Primary ILD Differential:

🔹️GGOs: NSIP, HP, Alveolar Proteinosis.

🔹️Nodular Septal Thickening: Sarcoidosis.

🔹️Tree-in-bud / Centrilobular: HP.

🔹️Bilateral Consolidations: Organizing Pneumonia (OP).

🔹️Diffuse Nodules/Miliary: Miliary TB, Sarcoidosis.

🚩 Clinical Red Flags for Malignancy:

🔸️​Unilateral involvement: ILD is almost always bilateral and symmetrical.

🔸️​Bulky Lymphadenopathy: Hilar or mediastinal nodes larger than 2 cm are rare in simple ILD (except Sarcoidosis).

🔸️​Pleural Effusion: Common in lymphangitic spread; rare in most fibrotic ILDs.

🔸️​Steroid "Masking": A temporary response in lymphoma (the "disappearing tumor" sign) can be misleading.

🔸️​Absence of Volume Loss: Fibrotic ILDs (like UIP) typically show significant loss of lung volume; many mimics do not.

✅️ Diagnostic Strategies: ​When these "mimics" are suspected, the following steps are often necessary:

🔹️​PET-CT: To look for extrapulmonary primary sites or hypermetabolic lymphadenopathy.

🔹️​Serial Imaging: Malignancy will not resolve with steroids; in fact, steroids may "mask" symptoms in lymphoma temporarily (the "disappearing tumor" sign), leading to a false sense of security.

🔹️​TBBx / Cryobiopsy: In cases of diagnostic uncertainty, early invasive sampling is often the only way to avoid treating a malignancy as an inflammatory ILD.

02/04/2026

🫁 OSA- COPD Overlap Syndrome Vs COPD- Obesity Hypoventilation

Both conditions involve the intersection of chronic obstructive pulmonary disease (COPD) and sleep-disordered breathing, but they differ significantly in their underlying pathophysiology and clinical presentation. ​Understanding these distinctions is essential for tailoring effective management, particularly when applying the latest 2026 clinical guidelines.

✅️ ​Comparative analysis between Overlap Syndrome vs. OHS-COPD:

👉 OSA-COPD Overlap Syndrome:

🔹️Primary Mechanism: Recurrent upper airway collapse during sleep leading to intermittent hypoxia.

🔹️CO2 Status: Daytime PaCO2 is often normal (unless COPD is very severe).

🔹️Nocturnal Pattern: Cyclic "saw-tooth" oxygen desaturations associated with apnea/ hypopnea events.

🔹️PFT Profile: Primarily obstructive; lung volumes may be high (hyperinflation).

🔹️Right Heart Impact: Increased risk of pulmonary hypertension compared to OSA or COPD alone.

👉 COPD-Obesity Hypoventilation (COPD + OHS) "Triple Overlap" :

🔹️Primary Mechanism: Alveolar hypoventilation due to reduced chest wall compliance and blunted respiratory drive.

🔹️CO2 Status: Characterized by daytime hypercapnia (PaCO2 > 45 mmHg) not explained by other causes.

🔹️Nocturnal Pattern: Sustained, "steady-state" oxygen desaturation throughout the night.

🔹️PFT Profile: Combined obstruction and restriction; significantly reduced FVC and TLC due to obesity.

🔹️Right Heart Impact: Very high risk of severe pulmonary hypertension and Cor Pulmonale.

✅️ Key Pathophysiological Distinctions:

👉​1. OSA-COPD Overlap Syndrome: the patient suffers from both obstructive lung disease and obstructive sleep apnea. This "double hit" leads to more profound nocturnal hypoxemia than either condition alone.

📍️​Ventilation/Perfusion (V/Q) Mismatch: The underlying COPD causes baseline V/Q inequality, which is then exacerbated by the mechanical obstruction of the upper airway during sleep.

📍️​Inflammatory Synergy: Both conditions promote systemic inflammation, significantly increasing the cardiovascular risk profile.

👉 ​2. COPD-Obesity Nocturnal Hypoventilation: ​Often referred to as the "Triple Overlap" (COPD + Obesity Hypoventilation Syndrome), this represents a state of chronic ventilatory failure.

📍​Work of Breathing: The excessive adipose tissue on the chest wall and abdomen increases the mechanical load on the respiratory muscles, which are already disadvantaged by COPD-related hyperinflation.

📍​The Bicarbonate Buffer: Chronic nocturnal hypercapnia leads to renal compensation (increased HCO3^-), which further blunts the central respiratory drive, perpetuating daytime hypoventilation.

✅️ ​Clinical Implications for Management:

🔹️Diagnostics: Beyond standard polysomnography (PSG), nocturnal capnography or early morning ABG is vital for identifying the hypercapnia seen in the hypoventilation group.

🔹️​Therapy:

■ Overlap Syndrome: Usually responds well to CPAP to splint the airway open, combined with optimized bronchodilator therapy.

■ ​COPD-OHS: Often requires Bilevel Positive Airway Pressure (BiPAP) with a backup rate to assist with CO2 clearance, alongside aggressive weight management.

01/04/2026

Antifungal Therapy for ABPA

Based on the 2025-2026 ISHAM (International Society for Human and Animal Mycology) and GINA updates for Allergic Bronchopulmonary Aspergillosis (ABPA), here is the current evidence- based protocol for antifungal therapy.

✅️ ​Duration of Initial Antifungal Therapy:​The current standard for newly diagnosed acute ABPA or a first-time exacerbation is a minimum of 4 months.

🔹️​Monotherapy Approach: Recent guidelines now allow for Itraconazole monotherapy (200 mg twice daily) for 4 months as an alternative to oral corticosteroids (OCS) for the first-line treatment of acute ABPA to avoid steroid-related side effects.

🔹️​Combination Therapy: If OCS and antifungals are used together, the antifungal is typically continued for the full 4-month duration, even as the OCS is tapered (usually over 3–5 months).

🔹️​Monitoring: Treatment response should be assessed at 8–12 weeks using clinical symptoms, chest imaging (to check for clearance of infiltrates/mucus plugging), and a decline in total serum IgE (typically a 25%–50% reduction is considered a good response).

​✅️ When to Restart Antifungal Therapy:​Restarting therapy is indicated upon a relapse, which is defined by a composite of clinical, radiological,& immunological markers.

🔹️​Criteria for Restarting: ​You should consider restarting or escalating therapy if the patient meets the following:

■ ​Clinical: Sustained worsening of respiratory symptoms (e.g., increased cough, wheeze, or dyspnea) for ≥ 2 weeks.

■ ​Radiological: New pulmonary infiltrates or "finger-in-glove" opacities (mucus plugging) on CXR or CT.

■ ​Immunological: A rise in total serum IgE by ≥ 50% from the patient's stable baseline (even if the patient is asymptomatic).

✅️ ​Management of Relapse:

📍​First Relapse: You may restart the 4- month course of monotherapy (either OCS or Itraconazole).

📍​Frequent Relapses: For patients with recurrent exacerbations, combination therapy (OCS + Itraconazole) is recommended over monotherapy.

📍​Refractory Cases: If the patient relapses while on Itraconazole or fails to respond, switching to second-generation triazoles (Voriconazole or Posaconazole) is indicated. In these chronic/recurrent cases, antifungal therapy may be extended beyond 6 months, though this requires careful monitoring for azole resistance and toxicity (e.g., LFTs, neuropathy, or photosensitivity).

✅️ ​Summary Antifungal Dosing for Adults & Therapeutic Drug Monitoring (TDM) level:

🔹️Itraconazole: 200 mg BID, (TDM) > 0.5 --1.0 mg/L

🔹️Voriconazole: 200 mg BID, (TDM) 1.0 -- 5.0 mg/L

🔹️Posaconazole: 300 mg QD (Delayed-release), (TDM) > 1.0 mg/L

💥 Clinical Note: Therapeutic Drug Monitoring (TDM) is strongly recommended for Itraconazole after 2 weeks of therapy due to highly variable absorption.

23/02/2026

दुर्गम पहाडी क्षेत्रका ६२ वर्षीय पुरुष बिरामीलाई ३ महिनादेखि सास फेर्न गाह्रो हुने, खोकी लाग्ने, स्वास फेर्न गाह्रो हुने समस्या थियो र त्यसपछि उहा मेरो OPD आउनुभयो।
PFT द्वारा COPD पुष्टि भयो।
Following

04/02/2026

Pressure-Controlled Ventilation (PCV) vs Volume-Controlled Ventilation (VCV)

Adult Patients with Acute Respiratory Failure
📚 Systematic Review & Meta-analysis (Medicine®, 2025)

📌 Bottom Line

🫁 PCV and VCV are both safe and effective when used correctly
⭐ PCV may be preferable in ARDS, but protective ventilation principles remain the cornerstone of care.

Saleem N. Hamilah

# respiratorycare